This article is more than 5 years old. Information may no longer be current.
SAVE study will investigate effects of CPAP on CV events
Click Here to Manage Email Alerts
Royal Philips has completed enrollment of 2,500 patients worldwide for a large study that will investigate the effects of continuous positive airway pressure on the prevention of MI, HF and stroke in high-risk patients with moderate to severe obstructive sleep apnea.
The randomized, controlled, multicenter SAVE trial was launched in 2008. Researchers enrolled patients from 84 medical facilities in seven countries. The study was designed to assess treatment of sleep apnea with continuous positive airway pressure (CPAP) and standard care compared with standard care alone and the effects on CV outcomes including MI, HF and stroke during a period of 2 to 7 years, according to a press release.
“We are looking forward to what the results could mean to the millions affected with these diseases around the globe,” Doug McEvoy, MD, senior director of the Adelaide Institute for Sleep Health in Australia and principal investigator for the SAVE study, stated in the release.
“The results of this study could radically change clinical practices and approaches to both sleep apnea and CV health,” Mark Aloia, PhD, senior director of global clinical research at Philips Healthcare, stated in the release. “If the results prove positive, it will be a major advancement in determining whether [positive airway pressure] therapy has a role in preventing CVD and its progression in people with sleep disorder breathing.”
Disclosure: Royal Philips is the lead sponsor of the SAVE study. Philips has had an active role in training the various SAVE sites in CPAP adherence techniques.